A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression.

Trial Profile

A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs CP 601927 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2011 Planned end date changed from 1 Mar 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 22 Dec 2011 Actual patient number (162) added as reported by ClinicalTrials.gov.
    • 22 Dec 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top